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ImmunomodulationIn this review, a companion piece to our recent examination of choroid plexus (CP), the organ that secretes the
cerebrospinal ﬂuid (CSF), we focus on recent information in the context of reliable older data concerning the
composition and functions of adult human CSF. To accomplish this, we deﬁne CSF, examine the methodology
employed in studying the CSF focusing on ideal or near ideal experiments anddiscuss the pros and cons of several
widely used analogical descriptions of the CSF including: the CSF as the “third circulation,” the CSF as a “nourishing
liquor,” the similarities of the CSF/choroid plexus to the glomerular ﬁltrate/kidney and ﬁnally the CSF circulation
as part of the “glymphatic system.”Wealso consider the close interrelationship between the CSF and extracellular
space of brain through gap junctions and the paucity of data suggesting that the cerebral capillaries secrete a
CSF-like ﬂuid. Recently human CSF has been shown to be in dynamic ﬂux with heart-beat, posture and especially
respiration. Functionally, the CSFprovides buoyancy, nourishment (e.g., vitamins) and endogenouswaste product
removal for the brain by bulkﬂow into the venous (arachnoid villi and nerve roots) and lymphatic (nasal) systems,
and by carrier-mediated reabsorptive transport systems in CP. The CSF also presentsmany exogenous compounds
to CP for metabolism or removal, indirectly cleansing the extracellular space of brain (e.g., of xenobiotics like
penicillin). The CSF also carries hormones (e.g., leptin) from blood via CP or synthesized in CP (e.g., IGF-2) to
the brain. In summary the CP/CSF, the third circulation, performs many functions comparable to the kidney
including nourishing the brain and contributing to a stable internal milieu for the brain. These tasks are essential
to normal adult brain functioning.
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In this review, we focus on recent information in the context of
reliable established data concerning the composition and manifold
functions of adult human cerebrospinal ﬂuid (CSF). This review is a
companion to our recent treatise on the structure and function of
the choroid plexus (CP) that secretes the CSF (Spector et al., 2015).
Wewill not discuss children less than two years of age because the func-
tions, ﬂow and reabsorption of CSF in their development are not yet
fully studied (Bateman and Brown, 2012; Whish et al., 2015). Also,
due to the length consideration of this review, we do not comprehen-
sively treat spinal cord–CSF relationships and associated clinical
problems, e.g. syrinx; however, in this regard it is important to acknowl-
edge that Koyanagi and Houkin (2010), and Ushewokunze et al. (2010),
respectively, have thoroughly analyzed pathogenetic and surgical
aspects of syringomyelia. To understand properly the composition and
functions of CSF, we carefully deﬁne CSF (Table 1), examine the signiﬁ-
cant methodologic problems in studying CSF, exemplify and focus
on ideal or nearly ideal experiments among hundreds performed, and
explicate the differences between CSF formation by CP and the enor-
mous H2O exchange ﬂuxes in CNS (Davson et al., 1987: Bateman and
Brown, 2012; Spector et al., 2015).
As a means of exploring the numerous functions of CSF we employ,
in part, a historical approach discussing several widely used analogical
descriptions of the CSF as the “third circulation” (Cushing, 1925), the
CSF as a “nourishing liquor,” similarities between the CSF/CP on the
one hand and the renal glomerular ﬁltrate/kidney tubules on the
other, and ﬁnally the CSF circulation as part of the “glymphatic system”
(Iliff et al., 2012, 2013; Xie et al., 2013) (an analogy with the lymphatic
system).
In the Introduction section, we brieﬂy introduce these analogical
descriptions. In the body of the paper is a discussion of the issues in
detail, aswell as thepossibility of extra-CP CSF formation, andmolecular
exchange between the CSF and extracellular space of brain [ECSB]
(also called interstitial ﬂuid). Finally, throughout the reviewwe address
certain misconceptions about the CSF and brieﬂy mention, where
appropriate, the clinical implications of recent developments in under-
standing CSF composition and functions. Noteworthy is the fact that
the blood–CSF barrier (BCSFB) consists of the CP epithelial cells and
arachnoid membrane cells joined by tight junctions that inhibit theTable 1
Human CSF composition — selected examples.
1) Ions
a) Na+, Cl−, HCO3−, K+, Ca++, Mg++, Mn++
2) Vitamins
a) Vitamin C, folate, thiamine monophosphate, pyridoxal phosphate
b) Paradoxical transport (riboﬂavin, nucleosides and Cu+)
3) Peptides and proteins — transported from blood
a) Leptin, prolactin and IGF-1
4) Peptides and proteins synthesized in CP; released into CSF
a) Transthyretin, IGF-2, BDNF
5) Other growth factors and brain maintenance substances
a) Small RNA (90 species not present in plasma)
6) Proteins that diffuse from blood through barriers as a function of size
a) Albumin and immunoglobulinspassive ﬂux of H2O-soluble molecules (Spector et al., 2015). However,
there is no appreciable barrier to diffusion between CSF and ECSB
because the pial and ependymal linings contain gap junctions in animals
and humans (Whish et al., 2015). In humans, the CSF volume is about
150 ml with ~20% residing in the lateral, third and fourth ventricles.
The volume of the human ECSB is also ~150 ml (Davson and Segal,
1996). The ECSB, comprising ~15% of brain volume, is a tortuous conduit
among cells that slows down simple diffusion by ~50% in part due to
large matrix molecules (viscous) in the ECSB (Hladky and Barrand,
2014). Since cortical ECSB decreases progressively as brain size becomes
smaller (Greenberg et al., 1965), caution is in order when comparing
murine vs. human ISF–CSF dynamics. For a schematic diagram of the
relationship between ventricular CSF, ependyma and ECSB, the reader
is referred to Fig. 2 in the article by Spector and Johanson, 1989.
For centuries, theCSF has fascinated philosophers, andmore recently
anatomists, physiologists, biochemists and neurologists whohavemade
progress in deﬁning and understanding the CSF. With the development
of anesthesia, neurosurgeons became very interested in CSF. Harvey
Cushing synthesized the extant information in 1925 and correctly
identiﬁed CP as the source of CSF, the bulk ﬂow of CSF through the
ventricular system, and the exit of CSF through the foramina of Luschka
and Magendie (fourth ventricle) into the subarachnoid space with
subsequent absorption into venous blood. He termed this process the
“third circulation,” the ﬁrst being that of the blood; and the second,
the lymph. Cushing (1925) recognized the important role of the CSF
in providing buoyancy for the ~1.2 kg human brain, and so, by the
Archimedes principle, operationally only “weighing” ~45 g.
Around the same time, others (Stern and Gautier, 1921, 1922, 1923)
proposed the CSF as a “nourishing liquor.” This concept now has sub-
stantial merit because CSF contains certain essential substances includ-
ing several micronutrients (e.g., vitamin C, folate) (Spector, 2014;
Spector and Johanson, 2014), ions, peptides, proteins and ~90 varieties
of small RNA not found in plasma whose function(s) await determina-
tion (Gallego et al., 2012). These substances penetrate into the brain
from CSF, and are essential for brain health (Table 1). Of course macro-
nutrients (e.g., glucose, amino acids, and lactate) and many micro-
nutrients, hormones, vitamins and minerals are transported from
blood directly into the brain by specialized mechanisms in the brain
capillaries (Davson and Segal, 1996). Brain capillaries are joined by
very tight junctions and are the locus of the blood–brain barrier (BBB)
(Whish et al., 2015). Thus, except where there are specialized systems
that allow entry (and exit), both the BBB and BCSFB isolate themamma-
lian brain and CSF frommany H2O-soluble molecules (including drugs)
in the blood. Molecular transfer of drugs from blood into ECSB and the
CSF, respectively, through the BBB and ECSB depends on several impor-
tant factors: the size, charge, lipid solubility and plasma protein binding
of the molecule; and secondly, the afﬁnity of the molecule, if any, for
inﬂux and/or efﬂux transporters at the BBB and/or BCSF barrier as
described below (Spector, 2009, 2010; Spector and Johanson, 2006).
Several pioneering investigators (Pappenheimer et al., 1961, 1962)
introduced the technique of ventriculo-cisternal perfusion. They noted
the resemblance of the kidney tubules and CP, respectively, in handling
many molecules between glomerular ﬁltrate and blood, and between
blood and CSF. This led to the so-called “sink” analogy discussed
below. The largely protein-free glomerular ﬁltrate andCSF are dissimilar
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actively secreted by CP (Davson et al., 1987; Spector et al., 2015).
In many respects, however, the CP and kidney behave similarly. For
example, in humans, from the glomerular ﬁltrate (~200 l/d which
contains ~1 g of ascorbic acid [AA]), the ~700 g human kidneys (renal
tubules) reabsorb N99% of the AA, by an active transport mechanism
termed the sodium-dependent vitamin C transport system-1 (SVCT-1).
The ~2 g human CP, through which ﬂows ~12 l/d of blood containing
~45 mg of AA, extracts and secretes N50% of the blood AA into CSF by a
similar mechanism (SVCT-2) (Spector and Johanson, 2006, 2014). This
explains the ~4 times higher AA concentration in CSF than plasma.
In the reabsorbing renal tubules, the SVCT-1 is on luminal side; in the
secreting CP the SVCT-2 is on the abluminal or basal side (Spector and
Johanson, 2006, 2014).
On the other hand, the renal tubules and CP epithelial cells transport
many unneeded endogenous (e.g., inactivemetabolites) and exogenous
substances (e.g., penicillin) out of blood into urine, and out of CSF into
blood, respectively (Davson et al., 1987). For example, the main system
that transports plasma penicillin into urine (via tubules), and CSF peni-
cillin into blood (by CP), is the organic acid transporter-3 (OAT-3)
(Spector, 2010; Spector et al., 2015).
In thepast two decades, one grouphas repeatedly suggested that the
CSF in not secreted by the CP and does not ﬂow down the aqueduct of
Sylvius (Oreskovic and Klarica, 2010, 2014a, 2014b). They suggest that
CSF is secreted by and reabsorbed by the cerebral capillaries. This theory
is not consistentwith the older data reviewed in themagisterial reviews
byDavson and Segal (1996) andDavson et al. (1987), andwithmore re-
cent data (Mokgokong et al., 2014; Spector et al., 2015). In reviews, this
view of the BBB secreting true CSF has been thoroughly debunked by
Brinker et al. (2014); Bateman and Brown (2012); Hladky and
Barrand (2014); Spector et al. (2015) and by numerous neurosurgeons
(Tisell, 2005;Warf et al., 2012; Bateman and Siddique, 2014). These er-
roneous views are due to lack of understanding of well-established CP
functioning, questionable protocols in experimental work in heavily-
instrumented anesthetized cats, andmisinterpretation about CSF secre-
tion vs. H2O exchanges among the blood, brain and CSF (that are N100
times the rate of CSF secretion in both animals and humans)
(Bateman and Brown, 2012; Hladky and Barrand, 2014; Spector
et al., 2015). Moreover, there are evidently no mechanisms in cere-
bral capillaries in vivo (not withstanding heroic efforts to ﬁnd
them) to secrete CSF-like ﬂuid into the ECSB with subsequent ﬂow
into the CSF (Mokgokong et al., 2014). These issues are discussed in
detail below.
For over a century, there has been clear recognition of free exchange
of molecules mainly by diffusion, across ependymal and pial interfaces
on the one hand, and ﬂowing ventricular and subarachnoid CSF on
the other. This diffusion occurs through permeable “gap” junctions
(Whish et al., 2015). However, there is now convincing human data
that CSF ﬂow is not unidirectionally-smooth like a river but there is
bidirectional ﬂow (oscillatory) through the aqueduct of Sylvius with
the heart-beat, posture and especially inspiration (Table 2) (Dreha-Table 2
Recent advances in understanding CSF ﬂows.
1) Realization of CSF ﬂowing bi-directionally through Aqueduct of Sylvius
a) Inﬂuence of heart-beat, posture and respiration
2) Net CSF ﬂow in humans; ~0.4 ml/min (average)
3) Diurnal patterns of ﬂow from 0.2→ 1.0 ml/min — more at night
4) Renewed understanding of differences between H2O exchange across barriers
and the net production of CSF containing salts (catalyzed by carbonic anhydrase
in CP but not BBB)
5) Putative streaming of CSF in lateral ventricles
a) Directed growth factor delivery to speciﬁc regions of brain
b) Role of motile cilia at ependymal apical membrane
6) Better understanding of hydrocephalus/treatment and prevention
a) Role of mutations in ependymal ciliary apparatus (axoneme dynein)
b) Role of mutations in ependymal gap junction proteins (cadherin)Kulaczewski et al., 2015). On balance, the net ﬂow of CSF through the
ventriculo-subarachnoid system is, on average, ~0.4 ml/min (humans)
with more CSF secreted at night (Nilsson et al., 1992, 1994; Spector
et al., 2015). Therefore, the exchange of many substances between
CSF and ECSB depends on both diffusion through gap junctions in the
pia/ependyma linings and the to-and-fro motion of the CSF mixing
(Table 2).
Recently, the notion of a “glymphatic system” has been proposed
in mice and rats and extrapolated to humans based on heavily-
instrumented, anesthetized mouse and rat studies (Iliff et al., 2012,
2013). Their working model is that molecules do not mainly diffuse
bidirectionally between ECSB and CSF via the ependyma/pia by way of
the gap junctions; instead, most H2O-soluble molecules leave CSF
spaces and ﬂow into the ECS of the brain predominantly down arterial
sheaths (possibly the Virchow-Robin spaces) into ECSB and then, after
mixing with ECSB ﬂuids, ﬂow out of the brain via cerebral veins into
subarachnoid CSF. This concept is not strongly supported by evidence
to date. At most, it is a minor pathway, especially across the ependyma
where there are no large penetrating vessels andwhere substantial CSF-
ependymal exchange occurs (Hammarstrom, 1966; Spector, 1981;
Spector and Lorenzo, 1974: Proescholdt et al., 2000;Whish et al., 2015).
Finally, a recent study in mice provides exciting evidence that aged
brain transfers signals via CSF that in turn inhibits CP (presumably by
a feedback mechanism) from producing maintenance peptides and
proteins for the brain via CSF distribution (Baruch et al., 2014). Thus,
there is normally continual bidirectional ﬂow of ‘molecular information’
(biochemical signals) between CP–CSF and the brain, but this is com-
promised in aged mice (Baruch et al., 2014). If true in humans, this is
an especially promising new ﬁnding on intra-CNS information transfer
mechanisms mediated by CSF.
2. Deﬁnition of CSF
CSF is the secretion of CP (Johanson et al., 2008; Spector et al., 2015).
A small amount of ﬂuid, though, may come through the BBB into the
ECSB by diffusion (Mokgokong et al., 2014). CSF is principally made up
of Na+, Cl− and HCO3−with lesser amounts of K+, Mg++, Ca++; certain
vitamins (e.g., folate, AA, thiamine and pyridoxal monophosphates);
and peptides and proteins actively transferred into CSF from blood
(e.g., leptin) or synthesized in CP (e.g., transthyretin, insulin-like growth
factor [IGF], brain-derived neurotrophic factor [BDNF]) and then trans-
ferred into CSF (Table 1) (Spector and Johanson, 2013).
A very small quantity of plasma proteins diffuses into CSF from
plasma (e.g., albumin). Unlike plasma (~7 g protein/100 ml) or milky
lymph (~2 g protein/100 ml), the CSF has only ~0.025 g protein/
100ml—mainly albumin. Tomake up for the missing negative charges
on plasma proteins and the lower concentration of HCO3− in CSF, the Cl−
concentration is ~12 mM higher; also higher than plasma are the
concentrations of Mg++, AA and folate. However, CSF K+ concentration
is about 2/3 that in plasma. Truly impressive are the homeostatic mech-
anisms in CP and glia to keep the concentrations of crucial substances
stable in CSF–ECSB, e.g., for K+ (Verkhratsky and Butt, 2013). When
the salt-containing CSF is secreted by CP, H2O molecules are “dragged”
along to maintain osmolality (Spector et al., 2015).
3. Technical issues pertaining to CSF
In evaluating experimental and clinical data on CSF composition and
functions, several factors must be recognized (Table 3) as often contrib-
uting to less than ideal experimentation. First, anesthesia has very
complex direct and indirect effects on cerebral blood ﬂow, cerebral
function, body temperature and CSF production. Such effects depend
on the speciﬁc anesthetic, dose, and time of anesthesia (Davson et al.,
1987; Hladky and Barrand, 2014). Certain drugs also have large effects
on CPbloodﬂowand/or CSF production. For example, atriopeptin (atrial
natriuretic peptide) increases blood ﬂow to CP in anesthetized rabbits
Table 3
Methodological considerations in studying CSF composition and functions.
1) Effects of anesthesia
a) On cerebral blood ﬂow
b) On cerebral function
c) On CSF production and ﬂow
d) On diurnal variation in CP blood ﬂow and CSF secretion
2) Effect of drugs
a) Acetazolamide (Diamox) and other carbonic anhydrase inhibitors to curtail
CP formation of ﬂuid
b) Atriopeptin (atrial natriuretic peptide) and other neuropeptides to inhibit ion
transport and CSF production at the blood–CSF interface
3) Autonomic discharge and stress factors
a) Effects of adrenergic agonists and blockers on CP blood ﬂow and CSF
production
4) Effects of temperature, blood gases, pH, and osmolality on CP blood ﬂow and
CSF production
5) Tissue culture of neural stem cells or barrier cells —
dedifferentiation/emergence or loss of functions
6) Effects of instrumentation and body ﬂuid redistribution
a) Inﬂammation and brain trauma
b) Interference with normal functions like inspiration and gravitational
adjustments (e.g. microgravity)
c) Pressure injections (injectate volume or hydrostatic pressure effects)
7) Differences and similarities between human and rodent brain
a) Size
b) Neuron/glial ratios
c) Size and function of astrocytes in rodents versus humans
d) Function of microglia (e.g., NO-generating system)
e) Distance from depth of brain to CSF
a) ~0.5 cm in rabbits (0.01 kg brain)
b) ~1.5 cm in human (1.2 kg brain)
f) New neuron production in human adult brain versus rodents
g) CP size and shape in rodents and other mammals, versus humans
8) State of brain/CSF at end of experiments
a) CSF composition (osmolality; and titer of neurohormones and Na+/K+)
b) Possible alteration of CP and BBB homeostatic functions
9) Importance of pharmacologic and physiologic principles
a) Dose–response and randomized controls
b) Time course of drug uptake from plasma
c) Differences between CSF production and H2O ﬂuxes
10) Withdrawal of CSF and analyses
a) Effect of sampled CSF volume on CNS physiology
b) Differential effects of single vs. multiple (serial) CSF aliquot collections on CSF
chemical composition
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other hand, doubles CP blood ﬂow but decreases CSF production by 55%
in chloralose-anesthetized rabbits, thus uncoupling CP blood ﬂow and
CSF secretion (Schalk et al., 1992; Faraci et al., 1990). Adrenergic
discharge and adrenergic agents both decrease CP blood ﬂow as well as
CSF production (Lindvall et al., 1979; Faraci et al., 1988).
Body temperature, blood gases (pH, pO2, pCO2) and plasma osmolal-
ity may affect CP blood ﬂow and alter CSF production/ﬂow. An excellent
example of these effects is the body temperature studies by Snodgrass
and Lorenzo (1972); as body temperature declined in anesthetized
cats, so did CSF production. This is expected since CSF formation is
directly linked to choroid epithelial metabolic rate, which decreases
proportionallywith temperature reduction. Another example is a recent
MRI study in conscious humans demonstrating that inspiration causes
marked to-and-fro motion of CSF through the aqueduct of Sylvius —
more than that due to cardiac pulsations. Thus, inspiration promotes
mixing in the ventricular compartment (Table 2; Dreha-Kulaczewski
et al., 2015). During anesthesia, with slower and shallower breathing,
this mixing effect would be minimized.
Cell culture ﬁndings are well known to be occasionally misleading.
For example, brain capillaries in vivo do not normally express SVCT-2
or aquaporin 1; however, in tissue culture after several generations,
they dedifferentiate and express substantial SVCT-2 and aquaporin 1
(Spector, 2009; Verkhratsky and Butt, 2013). Instrumentation in the
CNS and pressure injections (from added injectate volume) can causeinﬂammation and bleeding that interfere with normal physiology,
leakage of CSF and hydrostatic pressure gradient abnormalities.
Between rodents and humans, there are profound differences in the
brain, not only in size, but also composition (Table 3) (Verkhratsky and
Butt, 2013; Herculano-Houzel, 2014). For example, the neuronal/glial
cell ratio is much larger in rodents. Protoplasmic astrocytes are 10×
larger in humans and have an order of magnitude more functionality
per astrocyte. Certain functions of themicroglia are different. Moreover,
the distance from the CSF to the deepest part of the brain is more than
3× greater in humans than rabbits. Also, the site of injection into CSF
of a test agent may be critically important in regard to the brain
response in translational investigations (Beard et al., 2015).
In human adults, new neuron production is limited to the dentate
gyrus (b2% /year) and striatum (b1%/year) (Emst et al., 2014). In
rodents, there is also new neuron production in the sub-ventricular
zone for transfer of interneurons via the Rostral Migratory Stream
(RMS) into the olfactory bulb (Emst et al., 2014). CSF ﬂow linked to
ciliary beating in rodent ventricles guides nascent neurons to olfactory
target regions (Sawamoto et al., 2006). However, it is worth noting
that CP histology, transport functions, CSF production rates/g and com-
position, frommice to humans, are remarkably similar taking brain size
into account. For example, the weight of CP in rabbits is 0.020–0.025 g
and ~2 g in humans; the corresponding brain weights are ~10 g and
1200 g, respectively. Accordingly, for rabbits and humans, as well as
rats, the CP/brain mass ratio is ~0.002.
Another important consideration for analyzing CSF is that humans
are upright and rodents are not. To understand the human CSF system,
gravitational forces must be taken into account. This effect of gravity is
critical in some long-term missions (N6 mo in space) during which
astronauts experience loss of visual acuity. In these astronauts subject
tomicrogravity, there is ﬂattening of the back of the eyeball and dilation
of the CSF-containing sheath around the edematous optic nerve head
(Mader et al., 2013). Due to putatively-elevated ICP in space ﬂight
(affecting ~1/2 of astronauts), the exact cause of the intracranial hyper-
tension importantly needs resolution (Kramer et al., 2015) due to the
potentially deleterious pressure effects of CSF pressure on the eye and
brain.
When evaluating experimental results, it is important of course to
know the state of the brain and CSF at the end of the experiment. Is
there inﬂammation or bleeding? These are crucial questions to evaluate
reliability. Finally, was the experimentation valid, with the appropriate
randomized controls, dose–response data and time courses? Straight
withdrawal of CSF (without systemic anesthesia) for CSF composition
studies does not suffer from these technical deﬁciencies. Thus, ideal
ethical experiments should be done in normal conscious animals or
humans, un-instrumented whenever possible, and with follow-up of
the state of subjects at the end of the investigation. There are not
many near-ideal experiments but there are a few in animals (e.g.,
Hammarstrom, 1966; Spector, 1981; Spector and Lorenzo, 1973, 1974;
Spector et al., 1977; Proescholdt et al., 2000) and humans (Nilsson
et al., 1992, 1994; Bateman and Brown, 2012; Dreha-Kulaczewski
et al., 2015). Moreover since there are signiﬁcant differences between
animals and humans, e.g., in the neuroanatomy of CSF drainage path-
ways (Coben, 1967), the ﬁndings on hydrodynamics in the former
need validation in patients whenever possible before drawing ﬁrm
conclusions about relevance to humans.
4. The ‘third circulation’
Despite challenge, the concept of the third circulation (Cushing,
1925) has stood the test of time. There is overwhelming evidence for
the adult CP secreting CSF (Table 1) that ﬂows through the ventricles
into the subarachnoid space, then over the top of the brain, with some
CSF going down to the lumbar sac. CSF exits the subarachnoid space
(due to pressure-dependent bulk ﬂow) into the blood at the arachnoid
granulations; and into the lymph system through the nasal cribriform
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routes depends on posture, pressure differentials and pathophysiology
(e.g., hydrocephalus) (Davson and Segal, 1996; Bateman and Brown,
2012; Bateman and Siddique, 2014; Hladky and Barrand, 2014).
Themajor CSFﬂow routes have been appreciated for nearly a century
since Cushing proposed the ‘third circulation’. Notwithstanding a
substantial body of evidence, some recent ﬂuid modeling has de-
emphasized the primary pathway of CSF percolation from the ventricles
to the basal cisterns (Oreskovic andKlarica, 2014a). Therefore, it isworth
reemphasizing (Table 2) that, unlike the Mississippi River that ﬂows
unidirectionally “downward”, the CSF has gentle but bidirectional ebbs
and ﬂows that create mixing. Overall, the net ﬂow in adults is through
the ventricles to the basal subarachnoid spaces (Bateman and Brown,
2012; Dreha-Kulaczewski et al., 2015) [see Hladky and Barrand, 2014
for a detailed discussion of bulk ﬂow, convection and diffusion]. Neuro-
surgeons understand well these anatomic and physiologic factors
because of the severe consequences of obstruction to the ventricular
ﬂow or overproduction of CSF (e.g., CP hyperplasia or papilloma) that
cause hydrocephalus (Tisell, 2005; Warf et al., 2012; Bateman and
Siddique, 2014; Spector et al., 2015). To ameliorate hydrocephalus in
some cases, neurosurgeons either remove both lateral CPs to decrease
CSF production (by presumably ~50%), or perform shunting of CSF to
the peritoneal cavity.
5. Immunologic and biochemical homeostasis of CSF: relationship
to ECSB
Since Cushing's work (1925), investigators have increasingly real-
ized the complexity of the CSF, its functional relationship to the ECSB,
and the hundreds of CSF functions that rely on transport, synthetic,
metabolic, and transformative processes in the CP or brain (Davson
and Segal, 1996; Ghersi-Egea et al., 1994; Spector et al., 2015; Spector
and Johanson, 2014).
A major difference between the CNS and the rest of the body is
normally there are very few immunoglobulins in CSF and negligible
white cells, unlike theplasma and lymph. Instead, the immunologic pro-
tection of the CNS is due to the turnover of CSF in close contact with the
ECSB and the extensive hyperactive microglial system in the brain
(Wake et al., 2009; Verkhratsky and Butt, 2013). Microglia are evenly
dispersed throughout the brain, have multiple protective and sculptur-
ing functions (e.g., removing unwanted, damaged or unused neuronal
boutons) and are “probably themost active cells in the brain, constantly
extending and contracting their processes to survey their environment”
(Verkhratsky and Butt, 2013). As a consequence, there is continual
cleansing of the ECSB. This is important for CSF physiology because
of the ready interchange between the ‘third circulation’ CSF and the
ECSB.
It is worth noting the hypothesis that in the elderly there is either
senescence and/or immune suppression of the brain's microglial sys-
tem. As a consequence, there is neuronal cell loss and build-up of dys-
functional proteins, peptides and substances like lipofuscin, with
adverse functional consequences e.g., Alzheimer's disease (Streit and
Xue, 2010; Kan et al., 2015). In other words, the CSF composition de-
pends not only on CP secretory processes but also the metabolic/transport
phenomena in neurons, microglia and astrocytes. Hence the appearance of
leukocytes in CSF is a sign of neural damage and/or inﬂammation and, as
noted above, important to evaluate after experimentally manipulating
the CNS.
A remarkable aspect of CSF is the complexity and function of the
homeostatic systems for many substances in CSF, e.g. K+, that depend
on activity by both CP and astrocytes. Two more examples of hundreds
are the relative stability of CSF concentrations of nucleosides (Spector
and Johanson, 2007) and certain vitamins (e.g., vitamin C, folate, thia-
mine and pyridoxal monophosphate) even when there are large ﬂuctu-
ations in plasma concentrations (Spector, 2014). Each one of this
myriad of transport/metabolism/regulatory systems is typicallyseparate, and biochemically complex and exists in the CNS ofmostmam-
mals from rodents to humans (Davson and Segal, 1996; Miller, 2004;
Spector, 2014; Spector et al., 2015). A monograph could be written
about each system. Lack ormalfunctioning of some of these systems is in-
compatible with life, e.g., the SVCT-2 in CP and neurons; or causes severe
disease, e.g., the lack of the folate transport system in CP (Spector, 2014).
6. CSF as a “nourishing liquor”
Nourishment, used literally, has two deﬁnitions: ﬁrst, food or other
substances necessary for growth and health of the body and mind.
Secondly, a narrower deﬁnition applies only to organic molecules. CSF
secreted by CP contains in a controlled fashion, inorganic ions (Na+,
Cl−, HCO3−, Ca++,Mg++,Mn++, and PO4- - -) aswell as certain vitamins,
glucose and other organic molecules (Table 1).
Although most macronutrients (e.g., glucose, amino acids, lactate,
fatty acids) and certain micronutrients (e.g., riboﬂavin, biotin, panto-
thenic acid and thiamine) enter the brain mainly from blood directly
through the BBB (Davson et al., 1987; Spector, 2009, 2014), a few
substrates, e.g., vitamin C and methyltetrahydrofolate [folate], are
transported solely or mainly from blood via the CP into CSF and then
diffuse slowly into ECSB for delivery to brain cells (Spector and
Johanson, 2007, 2014: Spector, 2014). This CP–CSF–ECSB route applies
to several micronutrients (e.g., ascorbate and folate), certain ions
(e.g., Na+, Cl− and HCO3−), and perhaps some trace elements, e.g.
Mn++, that when infused intravenously over ~1 h (as 0.9 mmole/kg
MnCl2) displayed initial uptake by CP, then CSF and ﬁnally brain regions
(Aoki et al., 2004). This CP–CSF–ECSB distributional nexusmust now be
considered as one of themajor conduits of supply for the brain (Spector
et al., 2015). Knock-out in animals (or in humans) of some of these
systems in CP is neurologically devastating or fatal. On a normal
human diet, for example, folate or vitamin C is unable to diffuse exten-
sively enough through the BBB if the folate or vitamin C systems in CP
are knocked out (Spector, 2014; Spector and Johanson, 2014).
Moreover, several of these CP ionic and micronutrient transport
systems, notwithstanding statements to the contrary, remain active
and efﬁcient into old age (Spector and Johanson, 2013). In elderly and
Alzheimer's patients, the ionic make-up of the CSF, the concentrations
of CSF vitamin C and folate (2–4× higher than plasma), and the CP
synthesis of transthyretin and transfer into CSF are maintained
(Spector and Johanson, 2013). In fact, there is more vitamin C in the
brain in normal elderly than younger humans by MRI spectroscopy
(Spector and Johanson, 2013). Thus, the notion of the CSF as nourishing
liquor for the brain has validity for many ions and a few organic mole-
cules, but not for macronutrients.
CP either transports peptides and proteins from blood into CSF
(e.g., leptin), or synthesizes others and releases them into CSF
(e.g., transthyretin, BDNF, and IGF-2). These peptides and proteins in
CSF can then readily diffuse into the brain (Johanson et al., 2011a,
2011b). Exact roles of these proteins in adults are not entirely clear
but as discussed below, their diminishing synthesis in rodents coincides
with brain “aging”. This phenomenon may occur in humans; in fact,
there is already preliminary evidence, a possibility that needs intense
investigation (Baruch et al., 2014). At present, the best hypotheses for
the presence of these peptides and proteins (e.g., IGF-1 and BDNF) in
adult human CSF (and ECSB) are to facilitate the low level replication
of neurons in the human dentate gyrus and striatum, and to maintain
and preserve neuronal function and longevity (Baruch et al., 2014).
Some CSF peptides (e.g., leptin and IGF-1)may also be transporting sig-
nals for on-and-off functions of target neurons in the brain (Rodríguez
et al., 2010; Johanson et al., 2011a).
7. Extra-choroid plexus formation of CSF
For decades, there has been an interest in an extra-CP source of CSF
(Hammock and Milhorat, 1976). One group even claims that most CSF
62 R. Spector et al. / Experimental Neurology 273 (2015) 57–68comes from cerebral capillaries into ECSB, with subsequent convection/
diffusion into the ventricles/subarachnoid space (Oreskovic and
Klarica, 2010, 2014a, 2014b). A review of voluminous data, however,
concluded that in rodents extra-choroidal CSF production was b10% of
total ﬂuid formation (Davson et al., 1987; Davson and Segal, 1996).
Particularly revealing has been the ﬁnding that in un-instrumented but
anesthetized rats, tracer concentrations of Na+ and Cl−, the principal
components of CSF, readily passed by active transport through CP into
CSF and then trans-ependymally into the surrounding brain (but not
across cortical capillaries) at early time points (Smith and Rapoport,
1986). A low-level diffusional exchange of Na+ from blood through
cerebral capillaries into ECSB (and back) could not be ruled out. The
permeability constant (P) for 22Na+ into the cerebral cortex was akin
to passively-distributed, H2O-soluble mannitol; and P 36Cl− was
only 1/2 that of mannitol, a much larger molecule (MW=180). This in-
dicated that Cl− passage through BBB is by simple diffusion. Later,
employing prolonged (10 min) in situ perfusion in heavy-instrumented
barbiturate-anesthetized rats, Ennis et al. (1996) conﬁrmed that Na+
did not pass through the BBB more rapidly than their larger passive
marker, α-aminoisobutyric acid (MW= 103); however, they detected
a small (~20%) saturable component when the Na+ concentration
was reduced from 138 (normal) to 0.2 mM.Whether such a low con-
centration of Na+ would change the permeability characteristics for
Na+ at the BBB is unknown, and whether this study actually mea-
sures transfer through the capillaries or just exchange with Na+ in
the capillaries, especially at 0.2 mM, are also unknown. These later
prolonged experiments of Ennis et al. (1996) must be viewed in the
context of the disadvantages associated with heavily-instrumented,
barbiturate-anesthetized rats.
Recently, Mokgokong et al. (2014) stated that for cerebral capillaries
to secrete Na+, Cl−, K+, and HCO3− into the ECSB with subsequent ﬂow
into CSF, there must be multiple speciﬁc ionic transporters at both the
luminal and abluminal sides of cerebral capillaries for net unidirectional
ion transport through BBB. To their credit, these authorsmade heroic ef-
forts to ﬁnd in cerebral capillary endothelium those ﬂuid-translocating
transporters existing in the CP and kidney. Using histological techniques
that easily detect ion transporters in the CP and kidney, they found no
evidence for such transporters in cerebral microvessels. Mokgokong
et al. (2014) then employed ultrasensitive immunohistology but
found only low-level evidence for just several ion transporters (AE2,
NBCe1 and NBCn1) in vivo, but with poor localization. In cultured
cerebral endothelial cells (rats), several other relevant ion transporters
were identiﬁed (Mokgokong et al., 2014). However, cerebral cortical
endothelial cells are well known to de-differentiate in culture. There-
fore, with these meticulous studies the authors found no evidence for
Cl− or K+ transport across cerebral capillaries, even in culture. Overall
this recent study ﬁts earlier conclusions (Davson and Segal, 1996;
Spector et al., 2015) of negligible evidence for extra-choroidal secretion
of ﬂuid via the ECSB into CSF, since Na+ and Cl− are not signiﬁcantly
secreted through cerebral capillaries.
Notwithstanding the above evidence, several authors persistently
deny that CP is the source of CSF, but rather maintain that CSF origi-
nates from cerebral capillaries (Oreskovic and Klarica, 2010, 2014a,
2014b). Their data and interpretations have been debunked by
Hladky and Barrand (2014), Bateman and Brown (2012), Brinker
et al. (2014) and Spector et al. (2015). We reiterate that a principal
error is not distinguishing H2O exchange from CSF formation
(Davson et al., 1987; Hladky and Barrand, 2014; Spector et al.,
2015). Water in humans and animals rapidly exchanges among the
blood, brain, and CSF. Water exchange is N100× the rate of formation
of CSF — a ﬂuid consisting mainly of Na+, Cl−, and HCO3−. In fact, in
one circulatory pass through rat CNS, N50% of H2O in blood exchanges
equally with H2O in the brain (Bateman and Brown, 2012; Spector
et al., 2015). Factors other than H2O channel transfer may be opera-
tive since aquaporins have not been identiﬁed in BBB endothelium or
at the basal side of adult CP.8. The choroid plexus/CSF axis analogy to glomerular ﬁltrate/kidney
J.R. Pappenheimer et al. (1961, 1962) demonstrated in conscious
goats that CP–CSF, in removing organic acids, from CSF behaves
like the kidney in removing such compounds from blood by saturable
transporters (Spector and Johanson, 1989). This analogy has substantial
merit. Human glomerular ﬁltrate (~200 l/d of clear ﬂuid containing
salts, vitamins, peptides, and amino acids as well as unwanted waste
catabolites and foreign molecules) is differentially handled. Water,
salts, vitamins and peptides are mainly reabsorbed whereas the waste
products leave in the urine. Moreover, speciﬁc renal abluminal trans-
porters “pump” (secrete) unwanted molecules from blood into urine.
On average, each gram of human kidney reabsorbs ~0.3 l/d of ﬂuid.
A similar physiology occurs in CP by comparable, sometimes identi-
cal,mechanisms. CP secretes ~0.2 l of CSF/d/g of CP (Table 1)— a process
similar to the carrier-mediated reabsorption of the ‘requisite’molecules
in glomerular ﬁltrate (into blood) by the renal tubules. However, there
are major differences. Renal reabsorption of H2O from glomerular
ﬁltrate, for example, depends on aquaporins and anti-diuretic hormone
whereas CP secretion is not or to a much lesser degree dependent on
AQP-1 on the apical (CSF) side of CP (Spector et al., 2015).
On the other hand, there are marked similarities between choroidal
and renal systems. AA is pumped into CSF by SVCT-2 and in the kidney
reabsorbed by SVCT-1, a closely-related transporter in structure and
function. In the kidney when the maximum ability of the tubules to
reabsorb AA is exceeded, the excess is excreted in the urine. This satu-
rating phenomenon provides an important part of the homeostatic
system for AA in the body (Spector and Johanson, 2006). Recently iden-
tiﬁed are many polymorphisms of SVCT-1 that, although all are func-
tional, display variations possibly explaining the differential sensitivity
of humans to scurvy (Timpson et al., 2010; Spector and Johanson,
2014). In other words, some individuals might reabsorb AA more efﬁ-
ciently from glomerular ﬁltrate and thus be less dependent on dietary
AA. Awaiting determination is whether (although likely) there are
similar polymorphisms of human SVCT-2 in CP and neurons, with func-
tional consequences. As noted above, AA exempliﬁes a substance that
enters the ECSB and then brain cells predominantly by the blood–CP–
CSF–brain route via SVCT-2 at the BCSFB. SVCT-2 is also responsible
for AA uptake by neurons containing ~10 mM AA compared with
~0.05 mM in plasma. The AA-concentrating system in central neurons
is powerful indeed (Spector and Johanson, 2014), relating to anti-
oxidant, cofactor as well as DNA metabolic roles.
A more complex system in both the kidney and CP/brain is the
handling of riboﬂavin. In human kidney, riboﬂavin is reabsorbed by
the tubules with a half-saturation concentration (KT) of ~0.2 μM
(Spector, 2014). When the plasma concentration rises above ~0.5 μM,
the renal tubular transporter is saturated and excess riboﬂavin is excret-
ed in urine. Moreover, riboﬂavin also has afﬁnity for OAT-3, a promiscu-
ous transporter that pumps penicillin and cimetidine into urine and
also, with a KT of ~70 μM for riboﬂavin, pumps the latter into urine
(Spector and Johanson, 2006; Spector, 2014). Thus, the kidney has a
dual system (i.e., reabsorption at the normal plasma concentrations
and secretion at higher blood concentrations) for regulating the excre-
tion and thus the blood concentration of riboﬂavin.
In the CNS, in many cases the transport/regulatory systems are ex-
tremely effective since the brain generally requires stable metabolite
and ion concentrations to function effectively (Davson et al., 1987;
Spector, 2009; Spector and Johanson, 2006, 2007, 2014). For example,
in the CNS, riboﬂavin entry into and exit from the brain are complex
processes but somewhat different than in the kidney. Riboﬂavin is
transported into the brain by a recently-cloned transporter at the BBB
with a KT of ~0.2 μM (Spector, 2014). Riboﬂavin is also transported
out of the brain and CSF by the promiscuous higher afﬁnity OAT-3 locat-
ed at both the abluminal side of brain capillaries and the apical side of CP
(Spector, 2014). Intraventricularly-injected riboﬂavin in conscious rab-
bits is cleared more rapidly from CSF by OAT-3 (and possibly other
63R. Spector et al. / Experimental Neurology 273 (2015) 57–68transporters) than penicillin. Clinically there are patientswithout the ri-
boﬂavin transport system at the BBB that suffer a severe neurological
disorder, due to the crucial roles that this vitamin plays in brain function
(Spector, 2014). Thus, like the kidney, the CNS has dual regulatory
transport systems for riboﬂavin at both the BBB and CP.
A similar situation exists for plasma nucleoside (e.g., uridine) and
copper transport into the brain with saturable inﬂux at the BBB, and
separate clearance (efﬂux) mechanisms for nucleosides and copper
from CSF at the BCSFB (Spector and Johanson, 2007; Fu et al., 2014).
These examples represent a plethora (hundreds) of similar functions
between the CP and kidney. There are many reasons, then, to call CP
the ‘kidney’ of the brain (Spector and Johanson, 1989).
9. Trans-ependymal and trans-pial exchange of materials between
CSF and ECSB
In documenting CSF–ECSB exchange of molecules in adults, three
critical points deserve emphasis. First, as noted above, H2O is freely
permeable among the blood, brain and CSF. Thus, looking at H2O
exchange is not relevant to CSF formation, circulation or exchange
with the ECSB for the purpose of this discussion, since the H2O content
of the brain under normal circumstances is constant. Second, since the
originally-documented free exchange of dyes between CSF and ECSB,
over 100 years ago (Saunders et al., 2014), the histologic explanation
is now clear for this ready exchange of physiologic ions, small H2O-
soluble molecules (100–300 D) and the slower (passive) diffusion
of even larger non-transported H2O-soluble molecules (e.g., inulin;
~5 kD) from CSF into ECSB, or ECSB into CSF: in adults there are large
gap junctions in the pia and ependyma whose permeable molecular
structure provides the route for CSF–ECSB diffusion and exchange
(Whish et al., 2015). The kinetics of CSF–ECSB exchange of H2O-
soluble molecules, not transported by carriers, is a complex mixed
process depending on the principles of diffusion (e.g., molecular size,
H2O-solubility and ionic nature) and tissue microarchitecture of the
cell–interstitium relationships (e.g., tortuosity and viscosity of the
ECSB matrix). Hydrodynamic factors affecting molecular movement
throughout ECSB relate to heartbeat, respirations, posture and time of
day. Passivemolecular exchange and diffusion (but not CNSH2Oﬂuxes),
it must be emphasized, is a slow process. In CSF–ECSB molecular
exchanges, the experimental tracer equilibration with deepest parts of
the brain from CSF (~1.5 cm in humans) takes many hours or even
days (see Hladky and Barrand, 2014 and references therein for a
thorough discussion). And third, for best evaluation of CSF–ECSB molec-
ular exchanges, it is imperative to carry out nearly-ideal replicated
experiments to avoid misleading results due to the potential technical
problems described in Table 3.
To focus on near-ideal instructive experiments, Hammarstrom
(1966) injected intravenously 14C-ascorbic acid (AA) (the reduced
form of vitamin C found in plasma; Spector and Johanson, 2006) into
conscious mice and performed autoradiography at subsequent time
points. He showed that 14C-AA ﬁrst entered CP, then CSF, next the
brain closest to the CSF and ﬁnally the whole brain. Hammarstrom's
observationswere extended in several series of studies in conscious rab-
bits with either intravenous or intraventricular injection of 14C-AA
(Spector, 1981; Spector and Lorenzo, 1973, 1974; Spector et al., 1977).
Intraventricular injections (0.1 ml) in these studies were done under
sodium pentothal anesthesia; the rabbits awoke quickly thereafter.
Also the number of leukocytes in the clear cisternal CSF 2 h after the
injection was quantiﬁed and averaged at b50 cells/mm3, thus showing
minimal inﬂammation. For humans, there is compelling evidence both
direct and indirect, that the AA transport systems in the CP and brain
resemble those in mice and rabbits (Spector and Johanson, 2006,
2013). We also conﬁrmed that the passively-distributing mannitol,
sucrose and inulin in intraventricularly-injected conscious rabbits read-
ily diffused across the ependymal and pial interfaces into the brain as a
function ofmolecular size and time (2 vs. 4 h)withmannitol N sucrose Ninulin, as expected from the molecular size gradation (Spector and
Lorenzo, 1974; Spector, 1981).
In an elegant autoradiographic study in conscious rats into which a
catheter had been implanted 3 d before, Proescholdt et al. (2000) dem-
onstrated how inulin diffuses into rat brain after lateral intraventricular
CSF injections. They elegantly conﬁrmed an initial substantial diffusion
of the test marker through the ependyma, then gradually over time
deeper into the para-ependymal brain and, as the CSF ﬂowed into the
subarachnoid space, through the pia into the surrounding brain.
Although diffusion throughout the CNS was heterogeneous due to
pooling in subarachnoid spaces and the heterogeneous anatomy of the
brain, by 4 h the entire brain in these conscious rats was labeled with
radioinulin. With the larger brains of rabbits (10 g) and humans
(N1 kg), the process would take longer following ventricular adminis-
tration (CSF as a source). As noted above, when tracer 22Na+ or 36Cl−
was injected intravenously into un-instrumented but anesthetized
rats, there was a deﬁnitive rapid ﬂux of these ions through CP into ven-
tricular CSF, and thereafter through ependymal gap junctions into para-
ventricular brain (Smith and Rapoport, 1986). Because the CSF and ECSB
concentrations of Na and Cl are similar (~138 mM) and stable, these
“ﬂuxes are in reality exchanges between ventricular CSF and ECSB”.
Noteworthy (as discussed above) is that radiolabeled Na+ and Cl− in
plasma do not pass readily through the cerebral capillaries except by
minimal diffusion; this is consistent with no known transporter mecha-
nism for NaCl to penetrate the BBB. Altogether the data support sub-
stantial transfer of NaCl-rich ﬂuid inwardly across the BCSFB and then
the permeable CSF–brain interface, but not across the BBB into the CNS.
On the other hand, there is ready diffusion of waste products from
neural/glial metabolism, vectorially out of the brain from ECSB into
CSF. Two examples are homovanillic acid (HVA) from dopaminemetab-
olism and 5-hydroxyindoleacetic acid (5-HIAA) from serotonin metab-
olism. In both animals and humans, these metabolites have high
concentrations in the brain and lateral ventricles, less in the 3rd and
4th ventricles, and a very low level in the lumbar sac (Davson et al.,
1987). This is because the CP has efﬁcient transport systems to remove
HVA and 5-HIAA derived from the brain (Barkai et al., 1972). The afore-
mentioned example clearly documents a bidirectionalﬂowofmolecules
between the ECSB and CSF, in this case into CSF. Thus, there is not just
bulk ﬂow of CSF through the ventricles, cranial subarachnoid and spinal
spaces back into blood, but there are also passivemolecularmovements
into, and from, the CSF and ECSB. Moreover, molecules like HVA and
5-HIAA distribute not only by passive diffusion/convection within the
CNS but also are actively pumped out of ECSB by BBB transporters, and
out of CSF by CP transporters.
For an individual drug molecule, its penetrating characteristics into
the brain after intraventricular injection (or entry from blood into
CSF) will depend on lipid solubility, charge, size and ability to be
transported on carriers, or not. Take penicillin andmethotrexate, for ex-
ample, that rapidly disappear after intraventricular injection by bulk
ﬂow and carrier-mediated transport by OAT-3 in brain capillaries and
CP (Spector, 2010; Li et al., 2013). Accordingly, these drugs in transit
are actively-reabsorbed and thus appear to penetrate less deeply into
the brain from CSF, unlike molecules like mannitol that are not actively
removed but exit CSF simply by diffusion (minimal) and bulk ﬂow.
The statement that molecules in ventricular CSF “minimally enter
the brain parenchyma” via the ependyma reported by Iliff et al. (2012)
seems doubtful in many cases — certainly for passively-distributed
H2O-soluble molecules and those that do not pass though the BBB and
BCSFB except minimally by simple diffusion. This statement by (Iliff
et al., 2012) is based on short-term 30-min studies in heavily instru-
mented anesthetizedmice employingﬂuorescentmarkers (of unknown
characteristics) with molecular weights of ~1, 3, and 2000 kD. The
longer-duration CSF studies in conscious animals of extensively-
permeating non-electrolytes (with non-carrier transported mannitol,
sucrose and inulin) belie the conclusion by Iliff et al. (2012) of negligible
transependymal exchange.
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the CSF–ECSB as, in a sense, one large compartment (~300 ml of
CSF + ISF in humans) with the ECSB having many tortuous arms, like
the Buddhist Kwan Yin with a ‘thousand arms’. The human ECSB
makes up ~15% of brain volume, situated behind the BBB. When think-
ing about molecular ﬂuxes throughout this extracellular compartment,
there are four situations to consider. First, with substances like Na+,
Cl−or AA that do not pass through the BBB appreciably, or are not me-
tabolized or signiﬁcantly degraded, and are pumped into CSF in a steady
fashion so that theCSF concentration of thesemolecules is ~stable, there
is slow movement (mainly diffusion) over time (hours to days) from
CSF into even the deepest recesses of the ECSB; the integrated result is
approximate equalization of concentration throughout the entire CSF–
ECSB compartment. Moreover, at steady state there is continual ex-
change and mixing within the compartment but no net ﬂux between
ECSB and CSF. A predictive model of this situation was presented for
AA (Spector et al., 1977). This model, which assumed at steady state
that the CSF–ECSB was one compartment for AA, showed that the KT
(the half saturation concentration for AA transport by CP) was opti-
mized tominimize CSF AA ﬂuctuations in the face of varying blood con-
centrations of AA. Moreover, this model correctly predicted CSF and
brain AA concentrations when tested in vivo in rabbits (Spector et al.,
1977). Thus the AA system in CP andneurons, in series functionally, pro-
vided excellent homeostasis in the brain for AA. This is the reason that
the brain is the last organ to become depleted in dietary AA deﬁciency
(Spector et al., 1977). Many other transporters at the BBB and/or CP
also act as regulatory systems in that their one-half saturation concen-
tration is close to the blood level; thus if the blood concentration is
raised relatively less of the molecule is transported into CNS and vice
versa (Davson et al., 1987; Spector et al., 1977).
A second situation described by Barkai et al. (1972) is when the brain
synthesizes substances not present in nascent CSF, e.g., HVA and 5-HIAA,
that diffuse from the ECSB into CSF, and are then carried out of CSF by
active transport at the CP and bulk ﬂow into venous blood/lymph. This
is the so-called sink effect (i.e., sweeping or cleaning action) that lowers
the concentration of substances, endogenous ions as well as non-
electrolytes (Parandoosh and Johanson, 1982), in CSF to protect the
brain environment (Davson et al., 1987).
Third, in some cases the CSF serves as a donor or source for the brain.
This pertains to molecules in CSF either manufactured by CP like
transthyretin, IGF-2 and BDNF, or pumped into CSF from plasma,
e.g., IGF-1, prolactin and leptin. These molecules then all gradually
move (from ventricles or subarachnoid space) into the ECSB to carry
out functions in glia, neurons and endothelium.
Fourth, and ﬁnally, in considering molecular ﬂuxes within the CSF–
ECSB compartment, many H2O-soluble molecules including drugs and
toxins injected into blood are unable to pass through the barriers, or
if they can penetrate into CNS, do not accumulate to therapeutic
(e.g., penicillin) or toxic (copper) levels. In many cases, they are
pumped out of ECSB by extrusion systems in cerebral capillary endothe-
lia (e.g., by P-glycoprotein), and out of CSF by CP efﬂux transporters
(e.g., by OAT3); the compromise of these excretory systems may lead
to central buildup of uremic toxins (Hosoya and Tachikawa, 2011).
Xenobiotics are also enzymatically degraded by endothelial or epithelial
cells within these barriers (Ghersi-Egea et al., 1994). Still, many beneﬁ-
cial endogenous solutes distribute bidirectionally within the CSF–ECSB
compartment, and have a ‘protected sanctuary’ (free of toxins) in
which ECSB homeostasis occurs so that brain functions properly. On
the other hand, penicillin exempliﬁes a ‘foreign’ but therapeutically-
important drug largely excluded from the CSF–ECSB unless very large
amounts of the antibiotic are administered.
10. BCSFB and BBB drug transfer into and out of CSF and ECSB
Drug transfer into and out of the CSF (and ECSB) depends onmolec-
ular size, lipid solubility, ionic charge and protein binding; and also, onafﬁnity for inﬂux or efﬂux carriers at the BCSFB and BBB (Davson
et al., 1987; Spector, 2010). There are three types of carriers: facilitated
diffusion, primary or secondary active transporters, and receptor-
mediated transporters (often through vesicles).
Two examples of important molecular transport of foreign mole-
cules into CSF through the BCSFB are iso-ascorbic acid (IsoA) and
scyllitol. IsoA is a widely-used antioxidant which travels on the AA
system in CP into CSF, and thereafter diffuses into the ECSB (Spector
and Lorenzo, 1974). IsoA has ~20% the afﬁnity of AA for the SCVT-2
transporter at the CP and neurons. Thus ~20× the dose of IsoA vs. AA
is able to substitute as an anti-scorbutic agent in the brain since IsoA is
just as effective an enzyme co-factor, e.g., for dopamine hydroxylase,
as AA (Spector and Lorenzo, 1974). Secondly, the natural product
scyllitol (an isomer of myo-inositol) is now being tried as a CNS drug.
Scyllitol has the same afﬁnity as myo-inositol at the CP and BBB for
transfer into CSF and the ECSB (Spector, 1978).
Other water-soluble ionic drugs also readily enter the brain via satu-
rable carrier-mediated systems at the BBB. An example is the antihista-
mine diphenhydramine (DPH), widely employed as a sleep aid
(Goldberg et al., 1987). Unlike molecules like diazepam for anxiety
and thiopental for anesthesia, which are nearly completely cleared
from blood into the ECSB in one pass of the circulation because they
are highly lipid-soluble, DPH is actively transported at the BBB (by amo-
lecularly uncharacterized transport system) and achieves higher
concentrations in the ECSB and CSF than in plasma notwithstanding
substantial protein binding in the latter (Goldberg et al., 1987; Sadiq
et al., 2011). However, like riboﬂavin, DPH is rapidly cleared from CSF
by a separate system in CP (Goldberg et al., 1987).
To place these transport systems in pharmacologic perspective, one
needs to consider what happens to transported molecules that traverse
the BBB and BCSF barriers by processes other than simple diffusion
(e.g., carrier-mediated or endosomal-mediated). There are of course
two main barriers, and molecules can potentially be transported in
either direction. Glucose is transported from plasma through the BBB
and BCSFB by the GLUT-1 transporter in the cerebral capillaries and CP
basolateral membrane (Farrell et al., 1992). This is an example of
“both into CNS.” Penicillin, on the other hand, typiﬁes a molecule that
both cerebral capillaries and CP transport out of ECSB and CSF, respec-
tively, into blood — “both out of CNS”.
Bidirectional transport, a signiﬁcant feature of CNS barrier systems,
has a bearing on pharmacokinetics and vectorial distribution. Riboﬂavin,
nucleosides, copper and diphenhydramine (above) are molecules
transported into the ECSB by different speciﬁc systems in cerebral capil-
laries, but are also transported out of the CSF into blood by different
systems in CP. Moreover, molecules like AA can be transported into
CSF from blood via CP and thence diffuse into the ECSB but, in its normal
reduced form, is unable to broach the BBB for brain-inward transport.
Finally, P-glycoprotein in cerebral capillaries but not CP is highly active
in extruding (and thus excluding) a multitude of molecules from the
ECSB. Thus, the routes into and out of the brain and CSF tracked by
many molecules (that do not traverse the BBB and BCSFB by simple
diffusion) are, inmany cases, complex. Multiple permeability, transport,
vectorial and hydrodynamic factors, then, determine drug concentra-
tion in CSF and ECSB.
11. Bidirectional brain— choroid plexusmolecular information ﬂow
via CSF
A recent fascinating report suggests that aging brain puts out
‘signals’ into CSF that interfere with CP production of neurotrophic
molecules. Speciﬁcally, Baruch et al. (2014) demonstrated that aged
mouse brains switch from healthy interferon (IFN-II) signaling to IFN-I
signaling. By way of CSF distribution, IFN-1 caused the CP to slow
down the production and secretion into CSF of factors such as IGF-1
and BDNF, molecules that “support neuronal growth, differentiation
and survival” (Baruch et al., 2014). Presumably as a consequence,
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neurogenesis. This decline was prevented by reestablishment of IFN-
II-dependent CP activity that, in mice, had been lost in aging (Baruch
et al., 2014). Whether this occurs in human CP is yet to be established
but, if so, opens wide and actionable possibilities. In aged humans,
Baruch et al. (2014) corroborated a marked increase in IFN-II in CP at
post-mortem examination. At least in mice, this speciﬁc aging process
is preventable and shows once again the critical role played by the
CP–CSF axis not only in maintaining adult brain, but also in essentially
preventing neural decline in aging. This introduces the concept of
bidirectional signal (information) ﬂow in the brain–CSF–CP axis.
12. Ventricular transmission of cells and molecular signals
transported across ependyma and choroid plexus into CSF
The continual, directed ﬂow of CSF is essential for: i) delivering to
targeted CNS regions certain cells/factors transported into the ventri-
cles, and ii) maintaining the physical conﬁguration of the ventricular
system to assure proper CSF volume and dynamics. Although bulk
ﬂow through the core of the ventricles is rhythmically-driven by
cardio-respiratory pulsations (Bottan et al., 2012), the ﬁner movement
of CSF along the ventricular walls is energized by wave-like motion
of motile cilia projecting outward across the apical membrane of
ependymal cells. At least in rats, ependymal ciliary activity helps
provide a ‘guided ﬂow’ (streaming) of nascent neurons (derived
from subventricular neurogenic zones) rostrally to olfactory regions
(Sawamoto et al., 2006). Unlike in rodents, however, in adult humans
there is evidently no birthing of neurons in the subventricular zone
destined for transport down the Rostral Medial Stream for olfactory
renewal; thus, the need for such a ciliary-dependent mechanism to
modulate adult neurogenesis has not been demonstrated in humans.
Normal ependymal ciliary and gap junctional functions are needed
to provide the requisite development of ventricular shape and size,
and normal 3rd ventricle-aqueductal CSF ﬂow to the 4th ventricle.
Rare ciliary deﬁciencies in the axoneme motor protein dynein (Bryan,
1983), collectively known as primary ciliary dyskinesia (PCD), cause
hydrocephalus by attenuating cilia-promoted CSF streaming along
ependyma; this hydrocephalus, conﬁrmed by sonographic marking
(Wessels et al., 2003), is associated with aqueductal stenosis (Vieira
et al., 2012)). The insertionally-mutated axonemal dynein heavy chain
gene in mice (Mdnah5) also occurs in humans (DNAH5) with PCD
(Ibanez-Tallon et al., 2002). PCD-associated abnormal ciliary motion is
either absent, hypoactive or reversed. PCD is the hallmark of many
mouse ependymal ciliary defectmodels (Lee, 2013), but this Kartagener
syndrome with hydrocephalus is rare in humans, i.e. ~1/30,000
(Berlucchi et al., 2012; Bush, 2000; al-Shroof et al., 2001). The hpy
mouse model of post-natal hydrocephalus, like human PCD, has an
ependymal dynein-deﬁciency frequency of ~35%; and advantageously
(experimentally) lacks the respiratory ciliary problems (moving mucus)
that attend Kartagener syndrome. Murine models of PCD, by revealing
strain-speciﬁc differences in phenotype, inform on genetic mechanisms
that modify susceptibility to hydrocephalus linked to ciliary dysfunction
(Lee, 2013). On the other hand, ependymal gap junctional defects of the
cadherin gene disrupt the 3rd ventriculo-aqueductal conﬁguration and
functions, leading to congenital hydrocephalus in rodents as well as
humans (Rodríguez et al., 2012; Guerra et al., 2015). Clearly, the mole-
cular integrity of the ependymal proteins, dynein and cadherin, is essen-
tial to maintain normal ventriculo-aqueductal ﬂow and support certain
brain functions undergirded by supply (bulk ﬂow delivery) of CSF
neurotrophins.
Key neural functionsmodulated by CSF-borne peptides and proteins
include neuronal plasticity, immunomodulation and neurogenesis.
Neurotrophins and growth factors such as IGF-1, BDNF andVEGF are se-
creted by CP into CSF, and thenwhilemoving through the ventricles, are
taken up across the permeable ependymal interface into various regions
(e.g., hippocampus, caudate nucleus, hypothalamus, periventricularwhite matter and periaqueductal gray). Upregulation of the choroidal
content of peptides such as IGF-1, BDNF andVEGF, and their subsequent
release to CSF for distribution to neuronal targets, are likely part of
an integrated feedback system (sensory and effector components) in-
volving biochemical information processing by T cells in both the
brain and CP (Schwartz and Baruch, 2012). Thus, choroid epithelial
cells likely act as mediators of peptide signal transfer in an immuno-
modulatory process that ultimately buffers the brain behavior against
episodes of systemic (peripheral) stress. Moreover, as demonstrated
in adult animals, the CSF is an important medium for supplying factors
to regulate neurogenesis in the dentate gyrus and some subventricular
zones (Johanson et al., 2011a). Perhaps in humans, IGF-1 and BDNF
ﬂow from the CP–CSF nexus to stimulate nascent neuron production
in the sub-ventricular zone for the striatum (Emst et al., 2014). How-
ever, additional evidence is needed to bolster the notion that the
sub-ventricular zone in adult humans is a signiﬁcant generator of new
neurons for the brain.
13. The ‘glymphatic’ system: is there a quasi-lymphatic drainage of
CSF and ISF?
Recently, notwithstanding the overwhelming evidence for bidirec-
tional ﬂow of molecules between the CSF and ECSB via gap junction
pores in the ependyma and pia, the group led by Nedergaard has
made three startling claims based in large part on ﬂuorescent studies
in anesthetized, heavily-instrumented mice and rats (Iliff et al., 2012,
2013; Xie et al., 2013). First, these authors make the incorrect claim of
minimal exchange between CSF and the brain through the ependyma,
which ignores the evidence presented above. Proescholdt et al.
(2000) provided a convincing autoradiographic demonstration of
intraventricularly-injected 14C-inulin ﬂowing from the lateral ventricle
of conscious rats into periventricular brain, as a function of time; they
observed diffusion throughout the entire brain at 4 h. Second, the
Nedergaard group (Iliff et al., 2012, 2013) claims that CSF ﬂows mainly
down the sheaths of arteries from the pial side, then into the ECSB, ﬁnal-
ly returning back to the subarachnoid space via sheaths of veins carrying
smallmolecules and peptides out of the brain into CSF for exit into blood
by bulk ﬂow. They name this hypothesized ﬂow route the “glymphatic”
pathway analogous to the lymph system in the rest of the body. Third,
they also claim (Xie et al., 2013) that in 15 min after the onset of sleep
or anesthesia, the ECS of mouse brain expands from ~14% to 23%,
i.e., an ~60% increase based on observations of ﬂuorescent marker
penetration up to 0.2mm intomouse cortex. They generalize this obser-
vation to the entire brain, and suggest that one function of sleep is to
clear out the waste products of metabolism through the expansion
and increased ﬂow of CSF throughout the brain during sleep.
In response to their second claim about the existence of the
“glymphatic” system, Hladky and Barrand (2014) and Brinker et al.
(2014) make a convincing case that these arguments are unlikely to
be correct andmay not apply to humans. To summarize their objections
and our own critique of the hypothesized “glymphatic” circulation, it
should be noted that the lymphatic circulation (content, ﬂow and
anatomy) is nothing like the CSF composition, ﬂow and “anatomy.”
First, themilky lymph contains 100×more protein than CSF; moreover,
lymph formation is due to the passive non-speciﬁc outﬂow of protein
and smaller molecules out of the vascular circulation into tissue (e.g.
muscle) ECS (Starling mechanism) (Hladky and Barrand, 2014). From
the ECS, the lymph ﬂows into lymphatic vessels that depend on muscle
contraction, gravity and pressure factors to return lymph to venous
blood. In contrast, the CSF is an active secretion of CP that has a myriad
of functions. Second, the authors do not acknowledge decades of data on
ependymal/pial permeability and exchange as noted above. Third, there
is contrary data that molecular ﬂow is along the arterial sheaths into
subarachnoid CSF or is at least bidirectional in the peri-arterial sheaths.
Recent data by Whish et al. (2015) suggest that the para-arterial CSF is
stagnant. Fourth, others have not observed (with ﬂuorescent markers)
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are not consistent with their hypothesized “glymphatic” pathway.
Sixth, the mice in experiments by Iliff et al. (2012) were heavily instru-
mented and pressure injected; the condition of thesemice at the end of
the experiments was not reported. For further discussion, see Hladky
and Barrand (2014) and Brinker et al. (2014). To recapitulate, the notion
that there exists a “glymphatic” pathway for CSF exchange with ECSB
remains at best, a working hypothesis and, in our view, unlikely to be
more than a minor phenomenon of CSF dynamics. An analysis of the
extant data, e.g., the ideal or near-ideal experiments in conscious ani-
mals (Hammarstrom, 1966; Spector, 1981; Proescholdt et al., 2000)
suggests thatmolecularﬂux ofmolecules not transported by specialized
transporters is due mainly to diffusion through the ependymal and pial
gap junctions; and that this is themajor route of exchange between CSF
and ECSB (Whish et al., 2015).
The initial notion in the third part (above) of the proposed
“glymphatic”hypothesis is that the brain does not have a sophisticated im-
munological (clearance) system. In fact, the brain does. The brain is nor-
mally cleansed by microglia that are evenly and diffusely present
throughout the entire brain (Wake et al., 2009). These hyperactive cells
are continually extending and retracting their processes, taking up debris
(e.g., dead cells, damaged proteins and unused/injured synaptic boutons).
Moreover, at the BBB and CP there are carriers for peptides (Aβ40) and
small organic molecules that transport unneeded molecules out of ECSB-
CSF. At the ependyma and pia, molecules such as HVA and 5-HIAA diffuse
out of ECSB into CSF for removal by carrier-mediated transport and bulk
ﬂow. In Alzheimer's disease, the concentration of Aβ42 in CSF is on average
lower than innormal age-matchedcontrols. Active carrier-mediated trans-
port processes that remove Aβ from CSF (Pascale et al., 2011) do not re-
semble the passive lymph circulation. Thus, the notion of CSF being like
the lymphatic system is not a good analogy and should be abandoned.
The second part of the third hypothesis (above) of the Nedergaard
group, viz., that the ECSB during sleep and anesthesia increases by
~60%within 15min (Xie et al., 2013), seems an inappropriate global ex-
trapolation from studies of brains, in heavily-instrumented mice, to a
depth of 0.2 mm. Coupled to this notion is the claim that sleep “drives
metabolite clearance from brain.” Again Hladky and Barrand (2014)
and Brinker et al. (2014) argue against these conclusions.
Many physiologic parameters change during sleep. For example, in
humans, there is impressive diurnal variation in CSF production, more
at night. What happens in mice? Are the adrenergic blockade experi-
ments reported by Xie et al. (2013) really demonstrating that the adren-
ergic system is constricting the ECSB in conscious awake mice, or are
they just increasing CP blood ﬂow and CSF production? Second, imped-
ancemeasurements during sleep are not consistent with a 60% increase
in the ECS of the brain. Most challenging to their hypothesis is the ques-
tion: where does the increase in ECSB (with a composition similar to
CSF) come from? Since cerebral capillaries are basically impermeable
to NaCl (Smith and Rapoport, 1986), from what source would a 60%
increase in human ECSB (~90 ml) originate in 15 min? It probably
does not come from CP and CSF production. The human CPs makes
~0.4 ml/min. Even if CP production of CSF doubles during sleep and all
the extra CSF went into the ECSB, that volume would only be ~6 ml in
15min. SeeBrinker et al. (2014) andHladkyandBarrand (2014) fordetailed
comments on these points. Finally, how about naps? Ten-minute naps dur-
ing the daytime formanyhumans are refreshing. In that time frame, is there
a huge expansion of the ECSB and a signiﬁcant increase inmetabolite clear-
ance? To summarize the proposed ‘glymphatic system’, based on extant
data and the collective considerations addressedabove, it seemsunwarrant-
ed to conclude that the entire brain ECSB during sleep expands by 60% in
15 min, thereby metabolically cleansing the whole CNS.
14. Viewpoint perspective on the cerebrospinal ﬂuid
Rather than looking at CSF as part of a glymphatic or quasi-
lymphatic system, perhaps a good way to view CSF is that of amultifunctional ﬂuid in close contact and interacting with the ECSB.
In many respects, the CSF–ECSB can be considered a single ‘collec-
tive’ compartment. In other words, holistically, the CSF and ECSB
should not be considered alone but rather as a combined but some-
times inhomogeneous compartment. However, for certain molecules
(e.g., K+ and AA) that are continuously secreted by CP into the ven-
tricles and leave CNS by routes noted above, there are sometimes
large ﬂuctuations in their concentrations in local regions of the
ECSB due to, e.g., intense neuronal activity (Verkhratsky and Butt,
2013). In practice, however, such inhomogeneities are quickly re-
solved by astrocyte buffering and diffusion of solute away from the
highly active site. On the other hand, the concentrations of some
molecules, especially those destined for excretion out of CSF, are rou-
tinely quite inhomogeneous (e.g., HVA, 5-HIAA) in the CSF–ECSB
compartment. Also to be considered are the myriad of other func-
tions of the CSF, e.g., buoyancy, nourishment, and the transfer of
growth and neuronal maintenance factors having receptor targets
in various brain regions.15. Conclusion
In this review, we portray the composition and numerous functions
of CSF. These include an analysis of various analogical descriptions, the
importance of CP in secreting CSF, and the ready CSF–ECSBmolecular
exchange. To do this, we focused on often-ignored methodological
issues and used exemplary experiments to provide the best evidence
for conclusions relevant to human CSF. We also consider the impor-
tance of the ECSB with its continuously-active microglial, neuronal
and astrocytic cells affecting CSF composition. In actuality, the for-
mation, ﬂow and reentry of CSF into the blood was reasonably well
described by Cushing's description as a ‘third circulation’, updated
by Davson and Segal (1996), and now made current by ourselves
and others (Hladky and Barrand, 2014; Spector et al., 2015; this
review).
Human CSF also has multiple other functions for brain health. These
include buoyancy for protection against blows to the head, transfer
of micronutrients like certain vitamins and minerals from blood into
CSF and thence into the ECSB, conveyance of large signaling and
chaperoning molecules from blood (e.g., hormones) or synthesized in
CP (e.g., transthyretin) into CSF, and removal of unnecessary molecules
in the brain (e.g., HVA, 5-HIAA or excessive amounts of Cu+, riboﬂavin
or nucleosides). CSF is also involved in the transfer bidirectionally
(Schwartz and Baruch, 2012) of immunoregulatory molecules between
the brain and CP, with compensatory responses from CP via CSF
(e.g., BDNF and IGF) stimulating the brain (Baruch et al., 2014) and
helping it adapt to stress. Moreover, theremay be streaming (guidance)
processes for CSF in the lateral ventricle that transfer growth-promoting
substances fromCP to their proper targets— aided by ependymal ciliary
beating (Sawamoto et al., 2006). This streaming hypothesis concept
must be reconciled (integrated) with CSF mixing due to heart beat, res-
piration and posture in humans. In summary, like the kidney regulation
of plasma composition and ﬂuid dynamics, the CP–CSF ﬂow axis has
many diverse extracellular ﬂuid functions that critically modulate the
brain from adulthood into aging.Conﬂicts of interest
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